FDA grants Priority Review for daratumumab combination in multiple myeloma

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Genmab A/S announced FDA granted a Priority Review for the supplemental Biologics License Application for the use of daratumumab (Darzalex) in combination with bortezomib, thalidomide, and dexamethasone as treatment for patients newly diagnosed with multiple myeloma who are candidates for autologous stem cell transplant.

To access this subscriber-only content please log in or renew you subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
In This Issue

YOU MAY BE INTERESTED IN

President Joe Biden April 9 announced his FY2022 budgetary plans for ARPA-H—Advanced Research Projects Agency-Health—a federal entity designed to “deliver breakthroughs to find cures for cancer and other diseases.” In his initial White House budget proposal—dubbed skinny budget, or budget-lite—Biden is requesting $6.5 billion to fund ARPA-H.  “The discretionary request calls for $6.5 billion to...